News | August 11, 2024
Zydus Lifesciences Q1 FY25 revenue up 21% YoY to reach Rs. 6,207.5 Cr
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
Our centers are performing as expected or even better
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
Aarogya program aims to improve the overall health outcomes for the community by offering comprehensive health screenings, diagnostic support, and increased health awareness
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Subscribe To Our Newsletter & Stay Updated
